Ohio University

Selective Kinase Inhibitor for the Treatment of Neurodegenerative Disorders

Overview

The human genome encodes more than 500 unique protein kinases, making them one of the largest superfamilies of signaling proteins. Protein kinases perform many diverse functions within the cell and serve to regulate a broad range of essential metabolic processes including signal transduction, protein activation, transport and secretion. Given their profound influence on cell biology, it is perhaps not surprising that aberrant or dysregulated kinase activity can lead to the onset of various diseases such as diabetes, inflammation, cancer and neurodegeneration. Protein kinases are therefore widely considered attractive targets for therapeutic intervention. Unfortunately, high structural similarity among protein kinases makes selectively targeting discrete kinases a considerable challenge.

The tR1 peptide is designed to block MARK2-mediated phosphorylation of tau at S262
The tR1 peptide (shown above) is designed to block MARK2-mediated phosphorylation of tau at S262

MARK2 is a serine/threonine protein kinase that phosphorylates the microtubule-associated protein tau. The tau protein is involved in facilitating the assembly, maintenance and stability of microtubules, which provide structure and stability to cells. Unfortunately, dysfunctional MARK2 activity often leads to hyperphosphorylated tau isoforms that can aggregate into higher order filaments known as neurofibrillary tangles (NFTs). If left untreated, NFTs can compromise the structural integrity of neurons, leading to the onset of neurodegenerative disorders such as Alzheimer’s Disease and frontotemporal dementia. Researchers at Ohio University have recently developed a synthetic peptide capable of selectively inhibiting the MARK2-mediated phosphorylation of tau. This 13 residue peptide, known as tR1, is a direct sequence mimic of the tau protein and inhibits tau phosphorylation at Ser262 in vitro and in cultured primary cortical neurons.

References

1Alzheimers Disease Facts and Figures

OU Reference 17027 View PDF

Published Patent

WO2018195376
U.S. Non-Provisional Patent Application filed October 15, 2019.

Inventors

Justin M. Holub, Ph.D. is an Associate Professor in the Department of Chemistry and Biochemistry at Ohio University. Dr. Holub received his Ph.D. from New York University in 2009 and completed his post- doctoral training at Yale University in 2013. Research in Dr. Holub’s laboratory focuses on the development of chemical tools such as synthetic biologics and pro-fluorescent ligands to study and manipulate protein-protein interactions. To facilitate these studies, researchers in the Holub laboratory use multidisciplinary approaches to design molecules that target the interfacial contacts between proteins. His research has led to the discovery of novel peptides and miniature proteins that inhibit therapeutically-relevant protein-protein interactions, thus helping to expand the ‘druggable’ proteome.

Robert Colvin, Ph.D. is Professor and Chair for the Department of Biology at Ohio University. Dr. Colvin received his Ph.D. in cell physiology from Rutgers University. As a post-doctoral fellow in cardiology at the University of Connecticut, Dr. Colvin was at the forefront of research on the then newly discovered cardiac Na+/Ca2+ exchanger and its role in cardiac disease. Upon completion of his post-doctoral training, Dr. Colvin focused his independent research on studying neurodegenerative diseases, specifically Alzheimer’s disease and stroke. His current research involves evaluating the neuronal mechanisms of zinc homeostasis - in particular, discovering the cellular mechanisms that are responsible for buffering cytosolic free zinc concentrations and those involved in the control and regulation of cytosolic zinc transients. This knowledge is important for providing a better understanding of the underlying mechanisms of neural degeneration in diseases such as stroke and Alzheimer’s disease.